Similar companies
Income Statement (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Revenue | 1.02B | 13.8% |
| Gross Profit | 531M | 35.1% |
| Cost of Revenue | 494M | 2.7% |
| Operating expense | 714M | 3.5% |
| Net Income | 169M | 1253.2% |
| EBITDA | 355M | 59.8% |
Balance Sheet (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Total Assets | 11.4B | 0.3% |
| Total Liabilities | 7.6B | 0.4% |
| Total Equity | 3.76B | 1.8% |
| Shares Outstanding | 63M | 0.6% |
Cash Flow (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Cash from operations | 331M | 24% |
| Cash from investing | -257M | 5.4% |
| Cash from financing | -161M | 184.8% |
EPS
Financial Highlights for Jazz Pharmaceuticals in Q2 '24
Jazz Pharmaceuticals reported a revenue of 1.02B, which is a 13.8% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 531M, marking a 35.1% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 494M, a -2.7% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 714M, showing a -3.5% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 169M, showing a 1253.2% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 355M, showing a 59.8% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Jazz Pharmaceuticals with growth in revenue, gross profit, and net income.
